AI
| Followers | 689 |
| Posts | 143817 |
| Boards Moderated | 35 |
| Alias Born | 03/10/2004 |
Wednesday, November 03, 2021 11:08:44 AM
Options Bulls Blast Pfizer (PFE) Stock on CDC Endorsement
By: Schaeffer's Investment Research | November 3, 2021
• Roughly 28 million kids aged 5 to 11 are now eligible for the Covid-19 vaccine
• Call volume is running at triple the intraday average
Pharmaceutical concern Pfizer Inc. (NYSE:PFE) is struggling for direction this morning, last seen up 0.1% at $45.52, after the U.S. Centers for Disease Control and Prevention (CDC) recommended the use of its Covid-19 vaccine on children ages 5 to 11. This makes approximately 28 million kids eligible for the shot, which will start being administered today. The security also received a price-target cut from SVB Leerink to $48 from $50, following its third-quarter earnings and revenue beat.
Pfizer stock yesterday surged to its highest trading level since September, though the shares remain far off their Aug. 18 all-time high of $51.86. A new ceiling seems to be emerging at the $46 level, though the 10-day moving average is still acting as a solid source of support for the equity. Year-over-year, PFE up 32.2%.
The options pits are overwhelmingly bullish towards Pfizer stock. Over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), PFE's 10-day call/put volume ratio of 9.54 sits higher than 94% of readings from the past year. This means calls have been getting picked up at a much faster -than-usual clip.
That optimism is reverberating today. So far, 63,000 calls have exchanged hands, which is three times the intraday average. Most popular by far is the weekly 11/5 46-strike call, followed by the November 50 call.
Options look like a solid choice for those wanting to weigh in on PFE's next move. The equity's Schaeffer's Volatility Index (SVI) of 26% sits higher than 19% of readings from the past 12 months, indicating options traders are pricing in low volatility expectations right now.
Read Full Story »»»
DiscoverGold
By: Schaeffer's Investment Research | November 3, 2021
• Roughly 28 million kids aged 5 to 11 are now eligible for the Covid-19 vaccine
• Call volume is running at triple the intraday average
Pharmaceutical concern Pfizer Inc. (NYSE:PFE) is struggling for direction this morning, last seen up 0.1% at $45.52, after the U.S. Centers for Disease Control and Prevention (CDC) recommended the use of its Covid-19 vaccine on children ages 5 to 11. This makes approximately 28 million kids eligible for the shot, which will start being administered today. The security also received a price-target cut from SVB Leerink to $48 from $50, following its third-quarter earnings and revenue beat.
Pfizer stock yesterday surged to its highest trading level since September, though the shares remain far off their Aug. 18 all-time high of $51.86. A new ceiling seems to be emerging at the $46 level, though the 10-day moving average is still acting as a solid source of support for the equity. Year-over-year, PFE up 32.2%.
The options pits are overwhelmingly bullish towards Pfizer stock. Over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), PFE's 10-day call/put volume ratio of 9.54 sits higher than 94% of readings from the past year. This means calls have been getting picked up at a much faster -than-usual clip.
That optimism is reverberating today. So far, 63,000 calls have exchanged hands, which is three times the intraday average. Most popular by far is the weekly 11/5 46-strike call, followed by the November 50 call.
Options look like a solid choice for those wanting to weigh in on PFE's next move. The equity's Schaeffer's Volatility Index (SVI) of 26% sits higher than 19% of readings from the past 12 months, indicating options traders are pricing in low volatility expectations right now.
Read Full Story »»»
DiscoverGold
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
